Ads
related to: sarcoma- Mechanism of Action
Learn about the MOA
of a new treatment option
- Dosing & Administration
Learn about dosing and
administration now
- Mechanism of Action
Search results
Galapagos selects Adaptimmune T-cell therapy for $665M biobucks collab
FierceBiotech· 3 days agoAdaptimmune was facing a financing cliff until Galapagos walked in with a sprawling licensing deal...
Evaluating Tumor Heterogeneity with a High Throughput Pipeline
The Scientist· 12 hours agoThe success of nonclinical drug testing relies heavily on using models that accurately recapitulate complex biological processes. With the passing of the Food and Drug Administration (FDA) Modernization ...
Cleve Jones: An Activist for All Seasons | Bohemian | Sonoma & Napa Counties
North Bay Bohemian· 5 days agoCleve Jones came striding across the lawn toward the outdoor patio behind the Russian River Senior...
Anthem Hero at Hadlock: Kennebunk kid battling cancer celebrated at Sea Dogs Game
Gannett via AOL· 4 days ago“Jackson has been through so much over the last year, and we are inspired by his perseverance in...
Attleboro mom gifts dogs to sick children in memory of daughter
NBC 10 Providence· 3 days agoAn Attleboro mom who lost her teenage daughter to cancer is doing all she can to keep her legacy...
BioInvent to Host Virtual KOL Event to Highlight Recently Presented Efficacy Data from BioInvent's...
Digital Journal· 4 days agoLUND, SWEDEN / ACCESSWIRE / May 30, 2024 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy,
Small Business - Salisbury Post | Salisbury Post
The Salisbury Post· 24 hours agoData show favorable safety and feasibility in 68 heavily pre-treated patients with R/M-HNSCC (Intention-to-Treat population; “ITT”) who received RT-activated NBTXR3 followed by anti-PD-1 as a second-or-later line treatment48% ORR in evaluable
Small Business - Salisbury Post | Salisbury Post
The Salisbury Post· 17 hours agoMerus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today ...
GGB Research Day Showcases Work of Students and Labs
UB Reporter· 6 days agoEphraim J. Gardner, with his award-winning research poster for his study titled “Investigating Novel Players Involved in AR Cistrome Reprogramming.” Students and laboratories affiliated with ...
Newswise Expert | Cheryl London , Tufts University
Newswise· 7 days agoCheryl London, D.V.M., Ph.D., ACVIM, is the Anne Engen and Dusty Professor of Comparative Oncology and associate dean for research and graduate educati
